Stockscreener 앱 받기
98.51
0.78%
0.76
Veradermics Inc 주식(MANE)의 최신 뉴스
Veradermics (NYSE:MANE) Director Sells 750,000 Shares - MarketBeat
Veradermics (MANE) backer exercises $0.00001 per share warrants - Stock Titan
Veradermics (NASDAQ: MANE) insider sells stock in two August trades - Stock Titan
Veradermics (MANE) R&D chief enters insider ranks with no stake - Stock Titan
Veradermics (NYSE:MANE) Stock Price Down 7.9%Here's Why - MarketBeat
Form 144 | Veradermics(MANE.US) Insider Proposes to Sell 6.37 Million in Common Stocks - Moomoo
Veradermics (MANE) affiliate plans NYSE sale via BofA Securities - Stock Titan
Veradermics CEO Reid Alexander Waldman disposes of common shares worth $7.24 million - Bitget
Veradermics (NYSE:MANE) Insider Timothy August Durso Sells 43,500 Shares - MarketBeat
Veradermics (NYSE:MANE) CEO Reid Alexander Waldman Sells 67,500 Shares of Stock - MarketBeat
Veradermics(MANE.US) Officer Sells US$4.69 Million in Common Stock - Moomoo
Veradermics (MANE) CTO unloads tens of thousands of shares in preset trades - Stock Titan
Veradermics (MANE) CEO sells shares under preset trading plan - Stock Titan
Veradermics (MANE) Institutional Ownership 2026 - MarketBeat
Veradermics (MANE) affiliate lines up NYSE share sale - Stock Titan
Veradermics (NYSE: MANE) holder lines up $15M stock sale - Stock Titan
Veradermics, Inc SEC Filing (Aug 17, 2026) - Stock Titan
Veradermics (MANE) holder SR One sells 321,749 shares, cuts stake to 4.9% - Stock Titan
John Childs Sells 100,000 Shares of Veradermics (NYSE:MANE) Stock - marketbeat.com
Planned MANE (MANE) insider common stock sale and recent IPO activity - Stock Titan
Veradermics (MANE) director-linked trusts sell 100,000 shares of common stock - Stock Titan
Veradermics (MANE) Stock Forecast and Price Target 2026 - MarketBeat
Citi Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $160 - Moomoo
Needham Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $164 - Moomoo
Veradermics, Inc SEC Filing (Aug 12, 2026) - Stock Titan
Veradermics: Q2 Earnings Snapshot - theheraldreview.com
MANE SWOT Analysis: Financial Challenges and Competitive Landsca - GuruFocus
Veradermics Q2 Results: EPS of $(0.58) Beats Estimate - scanx.trade
Veradermics (NYSE: MANE) posts larger loss as cash surges above $800M - Stock Titan
Veradermics Announces Q2 2026 Financial Results in SEC 8-K Filing - Kalkine Media
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - BioSpace
Form 8K VERADERMICS For: 11 August By Investing.com - Investing.com Australia
Veradermics reports Q2 2026 net loss $23.5M; cash $819.9M funds operations into 2030 - TradingView
Veradermics' Q2 Net Loss Widens - marketscreener.com
Earnings Flash (MANE) Veradermics Posts Q2 Net Loss $23.5M, vs. FactSet Est of $26.8M Loss - marketscreener.com
IPO Databook: Veradermics (MANE US)Aug 2026 - Smartkarma
FMR LLC discloses 7.6% Veradermics Inc. (MANE) ownership in Schedule 13G - Stock Titan
Enterprise value to EBIT forward of Veradermics, Incorporated – NYSE:MANE - TradingView
Price to earnings forward of Veradermics, Incorporated – NYSE:MANE - TradingView
Price to sales forward of Veradermics, Incorporated – NYSE:MANE - TradingView
Enterprise value to revenue forward of Veradermics, Incorporated – NYSE:MANE - TradingView
Veradermics (MANE) Positioned to Disrupt Hair Loss Market - Yahoo Finance
Veradermics, Inc. (MANE): Six Months Later: Hair Today, Higher Tomorrow, 2026's Breakout Story - Smartkarma
Veradermics Falls 4.4% as Lock-Up Expiry Appears to Weigh on Shares - Moomoo
Certain Options of Veradermics, Incorporated are subject to a Lock-Up Agreement Ending on 3-AUG-2026. - marketscreener.com
14,570,076 Common Stock of Veradermics, Incorporated are subject to a Lock-Up Agreement Ending on 29-JUL-2026. - marketscreener.com
Veradermics, Incorporated's Lock-Up Period Set To End on August 3rd (NYSE:MANE) - marketbeat.com
Veradermics, Incorporated Revenue Breakdown – NYSE:MANE - TradingView
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months - Yahoo Finance
LifeSci Capital Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $170 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Veradermics shares climb 9% after encouraging female hair loss trial results (MANE) - MSN
Veradermics presents subgroup analysis of hair loss drug trial By Investing.com - Investing.com Canada
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy - Yahoo Finance
Veradermics Is Maintained at Buy by Citigroup - Moomoo
MANE Maintained by Citigroup -- Price Target Raised to $160 - GuruFocus
Why Veradermics Stock Fell Today - Quiver Quantitative
0.86%
0.31%
자본화:
|
볼륨(24시간):